StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MPLT$29.76+1.54%
Fair $29.76+0.0%

MPLT

MapLight Therapeutics, Inc.

Healthcare / BiotechnologyNasdaqGS

$29.76

+0.45 (+1.54%)

Fairly Valued+0.0%Fair Value $29.76Fund rank 34/100 · Data gapFallback financials|
SA 24/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-109.1M · quality 69.7/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 56/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

24/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

8/100

SEC 0%

Latest source: unknownPeriods: 2Warnings: 1unknown: 2
No SEC-backed annual rows; valuation uses fallback financial data. Limited financial history; valuation confidence should be treated as provisional. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. ROE is -35.2%, below the 5% threshold
Thesis & Journal · MPLTLocal privado en este navegador · MapLight Therapeutics, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.3B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-35.2%

↓

Gross Margin

N/A

•

Debt/Equity

0.01

↓
52-Week Range$30
$12$33

TradingView lightweight chart

MPLT price, volumen y niveles de valoración

Último $29.76Periodo +62.3%
Fair value: $29.76

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2024–2025 · 1 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

0.86x

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $-161.2M · FCF $-138.6M

2024-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts
MetricTTM
2025
2024
Income Statement
Net Income$-161.2M$-161.2M$-77.6M
EBITDA$-168.5M$-168.5M—
EPS-18.56-18.56-105.38
Balance Sheet
Debt/Equity0.010.01—
Current Ratio22.9122.91—
Cash Flow
Free Cash Flow$-138.6M$-138.6M$-79.6M
Returns
ROE-35.2%-35.2%40.1%
Valuation
P/B0.560.56—

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +62.3%

Total return

+62.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-105.38 → -18.56

Residual

+62.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+62.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.